Donate For Public and Patients Store Search

S016 - JAK Inhibitors: A New Frontier in Dermatology

Friday, March 1; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify and describe a new class of medications that will be useful in dermatology
  • Utilize JAK inhibitors for the treatment of alopecia areata, vitiligo, psoriasis, atopic dermatitis, sarcoidosis and granuloma annulare, and dermatomyositis and lupus.
  • Summarize the potential adverse effects of JAK inhibitors

Description

The recent development of Janus kinase inhibitors has led to new therapeutic options in dermatology. The application of Janus kinase inhibitors to common dermatologic diseases, with significant unmet medical need, will be presented, including the results of clinical trials and case series. Safety will be discussed. The audience for this session will be dermatologists whose practice involves the care of patients with alopecia areata, vitiligo, atopic dermatitis, psoriasis, sarcoidosis, dermatomyositis and lupus.

Disclosures

  • Armstrong, April W., MD, MPH: AbbVie – A(H), C(H), Data Safety Monitoring Board(H), I(Grants/Research Funding), SP(H); Amgen – A(H); Boehringer Ingelheim – Data Safety Monitoring Board(H); Bristol-Myers Squibb – C(H), I(Grants/Research Funding); Celgene – C(H), I(Grants/Research Funding); Demira – I(Grants/Research Funding); Dermavant Sciences – C(H); Eli Lilly and Company – C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – C(H); Genzyme Corporation – C(H); GlaxoSmithKline – C(H); Janssen Pharmaceuticals, Inc – C(H), SP(H); Janssen-Ortho Inc. – A(H), C(H), I(Grants/Research Funding); Leo Pharma Inc – C(H), I(Grants/Research Funding); Menlo Therapeutics – C(H); Merck & Co., Inc – A(H); Modernizing Medicine – C(H); NIH – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), C(H), I(Grants/Research Funding); Ortho Dermatologics – C(H); Parexel – Data Safety Monitoring Board(H); Pfizer Inc. – A(H), C(H); Regeneron – C(H), I(NC); Regeneron Pharmaceuticals, Inc. – SP(H); Sanofi – I(NC), SP(H); Science 37, Inc. – C(H); UCB – A(H), I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H);
  • Craiglow, Brittany Gareth, MD: Aclaris Therapeutics Inc. – A(H), C(Fees); Celgene – A(Fees); Concert Pharmaceuticals – C(Grants/Research Funding); Eli Lilly and Company – C(Fees); Pfizer Inc. – A(H), C(Fees), I(NC), SP(H); Regeneron Pharmaceuticals, Inc. – A(H), SP(H); Roivant Sciences – C(Fees); Summers Laboratories – O(H);
  • Damsky, William, MD, PhD: Eli Lilly and Company – C(Fees); Pfizer Inc. – I(Grants/Research Funding);
  • Harris, John, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Aclaris Therapeutics Inc. – I(Grants/Research Funding); Aclaris Therapeutics, Inc. – C(Fees); BiologicsMD, Inc. – C(H); Celgene Corporation – I(Grants/Research Funding); Combe Incorporated – C(Fees); Concert Pharmaceuticals – A(H); Dermavant Sciences – C(Fees), I(Grants/Research Funding); Dermira – I(Grants/Research Funding); EMD Serono – C(H); Genzyme Corporation – C(H), I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); Janssen Biotech – C(H); Leo Pharma Inc – I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novartis – C(Fees); Pfizer Inc. – C(H), I(Grants/Research Funding); Rheos Medicines – C(H), I(Grants/Research Funding); Stiefel a GSK company – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H); TeVido Biodevices, LLC – A(SO), I(Grants/Research Funding), SH(ST); Third Rock Ventures – A(H); Villaris Therapeutics, Inc – F(ST), I(Grants/Research Funding);
  • King, Brett Andrew, MD, PhD: Concert Pharmaceuticals – C(Fees), I(Fees); Dermavant Sciences – A(H); Eli Lilly and Company – C(Fees), I(Fees); Pfizer Inc. – A(Fees), A(H), C(Fees), I(Fees); Regeneron – SP(H);
  • Simpson, Eric Lawrence, MD: AbbVie – C(Fees), I(Grants/Research Funding); Boehringer Ingelheim – C(Fees); Demira – C(Fees); Dermavant Sciences – C(Fees); Eli Lilly and Company – C(Fees), I(Grants/Research Funding); Forte Biosciences – C(Fees); Galderma Laboratories, LP – I(Grants/Research Funding); Incyte Corporation – C(Fees); Kyowa Hakko Kirin Pharma, Inc. – I(Grants/Research Funding); Leo Pharma Inc. – C(Fees), I(Grants/Research Funding); Menlo Therapeutics Inc. – C(Fees); Merck – I(Grants/Research Funding); Pfizer Inc. – C(Fees), I(Grants/Research Funding); Pierre Fabre Dermo Cosmetique France – C(Fees); Regeneron – C(Fees), I(Grants/Research Funding); Sanofi Genzyme – C(Fees); Valeant Pharmaceuticals International – C(Fees);
  • Vleugels, Ruth Ann, MD: Pfizer Inc. – I(Fees);
Schedule
Friday, March 1
1:00 PM
Dr. King / The Clinical Impact of the JAK/STAT Pathway
1:20 PM
Dr. Harris / Vitiligo
1:40 PM
Dr. Craiglow / Alopecia Areata
2:10 PM
Dr. Simpson / Atopic Dermatitis
2:30 PM
Dr. Armstrong / Psoriasis
3:00 PM
Dr. Vleugels / Dermatomyositis and Lupus
3:20 PM
Dr. Damsky / Sarcoidosis and Granuloma Annulare
3:50 PM
Dr. King / Case Reports
Event Details
  • Date
    Friday, March 1
  • Time
    1:00 PM - 4:00 PM
  • Location
    Salon I
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Brett Andrew King, MD, PhD, FAAD
Speakers
  • April W. Armstrong, MD, MPH, FAAD
  • Brittany Gareth Craiglow, MD, FAAD
  • Eric Lawrence Simpson, MD, FAAD
  • John Harris, MD, PhD, FAAD
  • Ruth Ann Vleugels, MD, FAAD
  • William Damsky, MD, PhD